TY - JOUR AU - PADMASRI, B. AU - NAGARAJU, R. PY - 2022/09/07 Y2 - 2024/03/28 TI - FORMULATION AND EVALUATION OF NOVEL INSITU GEL SYSTEM IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS JF - International Journal of Applied Pharmaceutics JA - Int J App Pharm VL - 14 IS - 5 SE - Original Article(s) DO - 10.22159/ijap.2022v14i5.43792 UR - https://journals.innovareacademics.in/index.php/ijap/article/view/43792 SP - 62-68 AB - <p><strong>Objective: </strong>To develop <em>in-situ</em> gel formulations of Lornoxicam for sustained release to reduce the dosing frequency in the treatment of rheumatoid arthritis.</p><p><strong>Methods: </strong>The method of ion-sensitive <em>in-situ</em> gel formation was used in this study. Lornoxicam in situ gel formulations were prepared by varying concentrations of sodium alginate as a bio-degradable gel-forming polymer, CaCl<sub>2</sub> as a cross-linking agent, and chitosan, HPMCK<sub>4</sub>, HPMCK<sub>15</sub>, guar gum, gellan gum, xanthan gum, pectin were used as drug release rate controlling polymers. The formulations F11-F18 were assessed for physical appearance, pH, <em>in vitro </em>drug release, viscosity, <em>in vitro </em>gelling capacity, and drug content. FTIR, DSC, and<em> in vivo </em>drug kinetics studies were conducted for lornoxicam pure drug and optimized formulation.</p><p>R<strong>esults: </strong>Formulations showed an optimum viscosity that will allow ease of administration and swallowing. All formulations were shown pH between 6.7 to 7.3, floating lag time was 2-3 sec and floated for 12 h. <em>In vitro</em>, drug release studies were reporting that commercial sustained release formulation of lornoxicam released 99.92% drug in 8 h, and optimized formulation F11 released 99.52% of the drug over a 12 h extended period. FTIR studies revealed no interaction between drugs and excipients used. The results of <em>in vivo</em> kinetic studies are approving the better performance of the optimized formulation. The C<sub>max</sub>, T<sub>max</sub>, t<sub>1/2, </sub>and AUC values are confirming the same thing.</p><p><strong>Conclusion: </strong>Lornoxicam oral <em>in situ </em>gel containing chitosan as a drug release controlling polymer is a promising approach for the treatment of rheumatoid arthritis in a convenient dosage form with better patient compliance and therapeutic response.</p> ER -